A Phase 1b Multi-Center, Open-Label, Dose-Escalation, Prime And Boost Vaccination Evaluation of VRON-0200 Using Two Chimpanzee Adenoviral Vectors in Adult Participants With Chronic HBV Infection Who Are Currently Receiving HBV Nucleos(t)Ide Reverse Transcriptase Inhibitors
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs Elebsiran (Primary) ; VRON-0200 (Primary) ; Tobevibart
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Sponsors Virion Therapeutics
- 19 Nov 2024 According to a Virion Therapeutics media release, dose escalation Cohort 1 (low dose) and Cohort 2 (high dose) is enrolled and Cohort 3 is enrolling patients. Additionally company look forward to sharing more results in early 2025.
- 19 Nov 2024 According to a Virion Therapeutics media release, data from this study published as a late breaker poster presentation at The Liver Meeting 2024 (The American Association for the Study of the Liver), in San Diego, California, US.
- 19 Nov 2024 Results presented in the Virion Therapeutics Media Release.